Back to results
US 10,293,024 B2Granted
MAP kinase P38 binding compounds
AssigneeBlueberry Therapeutics Limited
InventorJohn Ridden
Life of this patent
Estimating the term…
Abstract
A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38α. The compounds are useful in binding to and inhibiting MAP kinase p38α, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.
Claims21
A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No:
- 1) or comprising a part of said amino acid sequence of 10 or more contiguous amino acids, or comprising a variant of said amino acid sequence or of said part thereof in which from 1 to 2 amino acids have been altered, wherein the residues of positions 2, 4, 8, 9, 10, 13 and 16 are conserved as compared to SEQ ID NO:
- 1 when said positions are present in said variant or in said part thereof, and wherein the compound binds to MAP kinase p38α, and wherein the compound has a molecular weight of less than 25,000 daltons.
A compound consisting of:
- the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No:
- 1),
- or a part of said amino acid sequence of 8 or more contiguous amino acids,
- or a variant of said amino acid sequence or said part thereof in which from 1 to 2 amino acids have been altered, wherein the residues of positions 2, 4, 8, 9, 10, 13 and 16 are conserved as compared to SEQ ID NO:
- 1, when said positions are present in said variant or in said part thereof,
- and wherein the compound binds to MAP kinase p38α.
3 more elements
Dependencies are inferred from the claim text.